trontinemab
Jump to navigation
Jump to search
Introduction
a human transferrin receptor 1-directed Brainshuttle module
Clinical trials
- phase 3 trial[3]
More general terms
References
- ↑ Grimm HP, Schumacher V, Schafer M et al Delivery of the Brainshuttle amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans. MAbs. 2023 Jan-Dec;15(1):2261509. PMID: https://pubmed.ncbi.nlm.nih.gov/37823690 PMCID: PMC10572082 Free PMC article.
- ↑ Muliaditan M, van Steeg TJ, Avery LB et al Translational minimal physiologically based pharmacokinetic model for transferrin receptor-mediated brain delivery of antibodies. MAbs. 2025 Dec;17(1):2515414. PMID: https://pubmed.ncbi.nlm.nih.gov/40568753 PMCID: PMC12203839 Free PMC article.
- ↑ 3.0 3.1 A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease ClinicalTrials.gov IDNCT07169578 https://www.medpagetoday.com/clinical-trial-finder/study/nct07169578